RECRUITING

Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers

Description

This phase I trial is evaluating a new imaging tracer (68Ga-FAPi-46) with positron emission tomography (PET)/computed tomography (CT) to determine where and to which degree the tracer (68Ga-FAPi-46) accumulates in normal and cancer tissues (the biodistribution) in patients with solid tumors or hematologic (blood) cancers. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, in the case of this research, 68Ga-FAPi-46. Because some cancers take up 68Ga-FAPi-46, it can be seen with PET. CT utilizes x-rays that traverse the body from the outside. CT images provide an exact outline of organs and potential inflammatory tissue where it occurs in a patient's body. Combining a PET scan with a CT scan can help make the image easier to interpret. PET/CT scans are hybrid scanners that combine both modalities into a single scan during the same examination.

Study Overview

Study Details

Study overview

This phase I trial is evaluating a new imaging tracer (68Ga-FAPi-46) with positron emission tomography (PET)/computed tomography (CT) to determine where and to which degree the tracer (68Ga-FAPi-46) accumulates in normal and cancer tissues (the biodistribution) in patients with solid tumors or hematologic (blood) cancers. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, in the case of this research, 68Ga-FAPi-46. Because some cancers take up 68Ga-FAPi-46, it can be seen with PET. CT utilizes x-rays that traverse the body from the outside. CT images provide an exact outline of organs and potential inflammatory tissue where it occurs in a patient's body. Combining a PET scan with a CT scan can help make the image easier to interpret. PET/CT scans are hybrid scanners that combine both modalities into a single scan during the same examination.

PET Imaging Study of 68Ga-FAPI-46 Biodistribution in Cancer Patients

Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers

Condition
Anal Carcinoma
Intervention / Treatment

-

Contacts and Locations

Los Angeles

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States, 90095

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Patients with the following suspected or diagnosed cancer types:
  • * Adrenal cancer
  • * Anal cancer
  • * Bladder cancer
  • * Brain cancer
  • * Breast cancer
  • * Cancer of unknown primary (CUP)
  • * Cervical cancer
  • * Cholangiocarcinoma
  • * Colorectal cancer
  • * Esophageal cancer
  • * Gastric cancer
  • * Head and neck cancer
  • * Hematologic cancer
  • * Hepatocellular carcinoma
  • * Lung cancer
  • * Medullary thyroid cancer
  • * Neuroendocrine neoplasias
  • * Ovarian cancer
  • * Pancreatic cancer
  • * Penile cancer
  • * Peritoneal cancer
  • * Pleural cancer
  • * Prostate cancer
  • * Sarcoma
  • * Salivary gland cancer
  • * Solitary fibrous tumor
  • * Skin cancer
  • * Testicular cancer
  • * Thymus cancer
  • * Thyroid cancer
  • * Urothelial cancer
  • * Uterus cancer
  • * Vaginal cancer
  • * Patients are ≥ 18 years old at the time of the radiotracer administration
  • * Patient can provide written informed consent
  • * Patient is able to remain still for duration of imaging procedure (up to one hour)
  • * Patient is pregnant or nursing
  • * Patient has underlying disease which, based on the judgment of the investigator, might interfere with the collection of high-quality data

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Jonsson Comprehensive Cancer Center,

Jeremie Calais, PRINCIPAL_INVESTIGATOR, UCLA / Jonsson Comprehensive Cancer Center

Study Record Dates

2027-09-07